JohnHerberBeigelMD
Internal Medicine • Bethesda, MDCritical Care Medicine, Infectious Disease
Physician
Dr. Beigel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
Bethesda, MD 20892Phone+1 301-451-9881
Education & Training
National Institutes of Health Clinical CenterFellowship, Critical Care Medicine (Internal Medicine), 2000 - 2004
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2001 - 2003
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1995 - 1998
The University of Toledo College of MedicineClass of 1995
Certifications & Licensure
MD State Medical License 2003 - 2026
DC State Medical License 2003 - 2013
OH State Medical License 1996 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Start of enrollment: 2010 Dec 01
- Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults Start of enrollment: 2011 Apr 01
Publications & Presentations
PubMed
- Navigating the path forward for evidence-based management of long COVID.Joseph J Breen, Robert W Eisinger, Sarah W Read, John Beigel, Tara N Palmore
Nature Immunology. 2025-03-19 - 8 citationsLicensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.Surender Khurana, Lisa R King, Jody Manischewitz, Olivia Posadas, Ashish K Mishra
Nature Medicine. 2024-10-01 - 2 citationsSARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert
The Journal of Infectious Diseases. 2024-09-23
Journal Articles
- Safety, Tolerability, and Pharmacokinetics of Radavirsen (AVI‐7100), an Antisense Oligonucleotide Targeting Influenza a M1/M2 TranslationRichard T Davey, John H Beigel, British Journal of Clinical Pharmacology
Press Mentions
COVID-19 Vaccines: From Nasal Drops to a Redesign, What 2023 Could Have in StoreJanuary 9th, 2023- Monkeypox Appears to Recede, but Risks and Uncertainties LingerSeptember 26th, 2022
- FDA to Stretch Monkeypox Vaccine Supply via Intradermal InjectionAugust 12th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
